Xylazine activates oxytocinergic but not vasopressinergic hypothalamic neurons under normal and hyperosmotic conditions in rats.
Role of central alpha2-adrenoceptors in the regulation of hypothalamic magnocellular cells was studied under hyperosmotic challenge elicited by hypertonic saline (HS). Rats pretreated with receptor agonist, xylazine (XYL), were injected intraperitoneally with different (low: 0.375, moderate: 0.75, high: 1.5 M) HS 30 min later. The activity of the paraventricular (PVN) and supraoptic (SON) vasopressin and oxytocin perikarya was established by Fos-dual-immunohistochemistry 60 min after HS administration. Results showed that 1/XYL is a potent stimulus for oxytocin but not vasopressin magnocellular cells under basal and weak hyperosmotic conditions 2/highHS completely overlaps the effect of XYL. In addition, XYL partially suppressed Fos expression in the parvocellular PVN cells activated by highHS. The data suggest that alpha2-adrenoceptors may play an important role in the regulation of oxytocinergic PVN and SON neurons under basal and weak hyperosmotic conditions and that alpha2-adrenoceptors may also participate in the control of PVN parvocellular cells under intense osmotic challenge.
Pirnik
Z
Z
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska str. 3, 833 06 Bratislava, Slovakia.
Jezova
D
D
Mikkelsen
J D
JD
Kiss
A
A
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D015870:Gene Expression / Q000187:drug effects; D016762:Genes, fos; D007031:Hypothalamus / Q000166:cytology / Q000187:drug effects*; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D009474:Neurons / Q000187:drug effects*; D009997:Osmotic Pressure; D010121:Oxytocin / Q000502:physiology*; D010286:Paraventricular Hypothalamic Nucleus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects; D013495:Supraoptic Nucleus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D014667:Vasopressins / Q000502:physiology*; D014991:Xylazine / Q000494:pharmacology*
D000316:Adrenergic alpha-Agonists; D018341:Receptors, Adrenergic, alpha-2; D014667:Vasopressins; D014991:Xylazine; D010121:Oxytocin